Serum proteomics screening intercellular adhesion molecule-2 improves intermediate-risk stratification in acute myeloid leukemia

Abstract

Background: The clinical risk classification of acute myelocytic leukemia (AML) is largely based on cytogenetic and molecular genetic detection. However, the optimal treatment for intermediate-risk AML patients remains uncertain. Further refinement and improvement of prognostic stratification are therefore necessary. Objectives: The aim of this study was to identify serum protein biomarkers to refine risk stratification in AML patients. Design: This study is a retrospective study. Methods: Label-free proteomics was used to identify the differential abundance of serum proteins in AML patients. Transcriptomic data were combined to identify key altered markers that could indicate the risk rank of AML patients. The survival status was assessed by Kaplan–Meier and multivariate Cox regression analyses. Results: We delineated serum protein expression in a population of AML patients. Many biological processes were influenced by the identified differentially expressed proteins. Association analysis of transcriptome data showed that intercellular adhesion molecule-2 (ICAM2) had a higher survival prediction value in the intermediate-risk AML group. ICAM2 was detrimental for intermediate-risk AML, regardless of whether patients received bone marrow transplantation. ICAM2 well distinguishes the intermediate group of patients, whose probability of survival is comparable to that of patients with the ELN-2017 according to the reference classification. In addition, newly established stratified clinical features were associated with leukemia stem cell scores. Conclusion: The inclusion of ICAM2 expression into the AML risk classification according to ELN-2017 was a good way to transfer patients from three to two groups. Thus, providing more information for clinical decision-making to improve intermediate-risk stratification in AML patients.

Intercellular adhesion molecule 2 as a novel prospective tumor suppressor induced by ERG promotes ubiquitination-mediated radixin degradation to inhibit gastric cancer tumorigenicity and metastasis

“…ICAM2, a transmembrane glycoprotein of the immunoglobulin superfamily, regulates immune responses and contributes to the occurrence of some cancers [ 32 ]. Recent studies have reported that ICAM2 is deregulated in multiple human cancers [ 33 ]. However, whether ICAM2 plays a role in GC development remains unclear.…”

Application of omics in the diagnosis, prognosis, and treatment of acute myeloid leukemia

“…Zhang et al [ 99 ]. used label-free quantitative proteomics in profiling the proteome of 10 BM plasma samples of newly diagnosed AML and 3 healthy donors.…”

Aging of Superficial Musculoaponeurotic System of the Face—Novel Biomarkers and Micro-CT Relevance of Facial Anti-Gravity Support

“…One of the first promoters shown to achieve uniform, high-level transgene expression in the vasculature of transgenic mice was that of the human intercellular adhesion molecule 2 gene (ICAM-2). This is a proteomic marker used until now to determine the aging phenomena that occur at the liver, acute myeloid leukemia, and lung levels [ 19 ]. In humans, this marker is a counter receptor for lymphocyte function-associated antigen-1 and can provide a costimulatory signal for T cell stimulation through the allogeneic major histocompatibility complex class II.…”